These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 101889)

  • 41. Conformational energy differences between side chain alkylated analogues of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane.
    Weintraub HJ; Nichols DE; Makriyannis A; Fesik SW
    J Med Chem; 1980 Mar; 23(3):339-41. PubMed ID: 7365752
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sulfur analogues of psychotomimetic agents. 2. Analogues of (2,5-dimethoxy-4-methylphenyl)-and (2,5-dimethoxy-4-ethylphenyl)isopropylamine.
    Jacob P; Shulgin AT
    J Med Chem; 1983 May; 26(5):746-52. PubMed ID: 6842515
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Conformational study of lysergic acid derivatives in relation to their hallucinogenic and antiserotonin activities.
    Kumbar M
    NIDA Res Monogr; 1978; (22):374-407. PubMed ID: 101885
    [No Abstract]   [Full Text] [Related]  

  • 44. A reevaluation of psychotomimetic amphetamine derivatives in humans.
    Cassels BK; Gómez-Jeria JS
    J Psychoactive Drugs; 1985; 17(2):129-30. PubMed ID: 4020537
    [No Abstract]   [Full Text] [Related]  

  • 45. Electrochemical study of the hallucinogen (+-)-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminopropane.
    Richter P; Morales A; Gómez-Jeria JS; Morales-Lagos D
    Analyst; 1988 Jun; 113(6):859-63. PubMed ID: 3218759
    [No Abstract]   [Full Text] [Related]  

  • 46. Bromo-DMA: the Australasian hallucinogen?
    Buhrich N; Morris G; Cook G
    Aust N Z J Psychiatry; 1983 Sep; 17(3):275-9. PubMed ID: 6580896
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Examination of the hallucinogen 2,5-dimethoxy-4-methylamphetamine.
    Phillips GF; Mesley RJ
    J Pharm Pharmacol; 1969 Jan; 21(1):9-17. PubMed ID: 4388198
    [No Abstract]   [Full Text] [Related]  

  • 48. Human hallucinogen interactions with drugs affecting serotonergic neurotransmission.
    Strassman RJ
    Neuropsychopharmacology; 1992 Nov; 7(3):241-3. PubMed ID: 1388647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of 2,5-dimethoxy-4-methylamphetamine on heart and smooth muscle contraction.
    Huang JT; Ho BT
    J Pharm Pharmacol; 1974 Jan; 26(1):69-70. PubMed ID: 4150941
    [No Abstract]   [Full Text] [Related]  

  • 50. Directional lipophilic character in a series of psychotomimetic phenethylamine derivatives.
    Nichols DE; Shulgin AT; Dyer DC
    Life Sci; 1977 Aug; 21(4):569-75. PubMed ID: 904435
    [No Abstract]   [Full Text] [Related]  

  • 51. Hallucinogens in Drug Discrimination.
    Baker LE
    Curr Top Behav Neurosci; 2018; 36():201-219. PubMed ID: 28484970
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of tolerance to the hallucinogenic effects of DOM.
    Angrist B; Rotrosen J; Gershon S
    Psychopharmacologia; 1974 Apr; 36(3):203-7. PubMed ID: 4844244
    [No Abstract]   [Full Text] [Related]  

  • 53. Relation of pharmacological and behavioral effects of a hallucinogenic amphetamine to distribution in cat brain.
    Idänpään-Heikkilä JE; McIsaac WM; Ho BT; Fritchie GE; Tansey LW
    Science; 1969 May; 164(3883):1085-6. PubMed ID: 5769766
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Conformational studies on phenethylamine hallucinogens: the role of alpha alkyl substitution.
    Makriyannis A; Knittel J
    NIDA Res Monogr; 1978; (22):464-78. PubMed ID: 101888
    [No Abstract]   [Full Text] [Related]  

  • 55. Bromo-DMA: new hallucinogenic drug.
    Delliou D
    Med J Aust; 1980 Jan; 1(2):83. PubMed ID: 7360100
    [No Abstract]   [Full Text] [Related]  

  • 56. Hyper-responsiveness to 5-HT2 agonists by tumour-linked arterioles in mice: consequences for tumor growth.
    Stücker O; Vicaut E; Teisseire B
    Int J Radiat Biol; 1991; 60(1-2):237-41. PubMed ID: 1677977
    [No Abstract]   [Full Text] [Related]  

  • 57. Effects of some centrally acting drugs on caeruloplasmin.
    Barrass BC; Coult DB
    Prog Brain Res; 1972; 36():97-104. PubMed ID: 4644035
    [No Abstract]   [Full Text] [Related]  

  • 58. delta7-Tetrahydrocannabinol, a non-psychotropic cannabinoid: structure-activity considerations in the cannabinoid series.
    Binder M; Edery H; Porath G
    Adv Biosci; 1978 Jul 22-23; 22-23():71-80. PubMed ID: 116883
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmacological receptors and the control of cell function.
    Stone TW
    Arch Int Pharmacodyn Ther; 1974 Aug; 210(2):365-73. PubMed ID: 4374143
    [No Abstract]   [Full Text] [Related]  

  • 60. Structure-activity relationships of phenethylamine hallucinogens.
    Nichols DE
    J Pharm Sci; 1981 Aug; 70(8):839-49. PubMed ID: 7031221
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.